Ignite Creation Date:
2025-12-25 @ 12:17 AM
Ignite Modification Date:
2026-02-24 @ 10:06 AM
Study NCT ID:
NCT03614858
Status:
RECRUITING
Last Update Posted:
2023-11-29
First Post:
2018-07-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Sponsor:
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
UnicarTherapy201807
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |